Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of the thromboprophylaxis with bemiparin 3,500 IU/d for 28 days compared to 8 days, in patients undergoing oncological abdominal/pelvic surgery

Next Previous
X
Search
Trial Profile

Multicentre, randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of the thromboprophylaxis with bemiparin 3,500 IU/d for 28 days compared to 8 days, in patients undergoing oncological abdominal/pelvic surgery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemiparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CANBESURE

    • Most Recent Events

    • 30 Apr 2010 Results have been published in the Journal of Thrombosis and Haemostasis.
    • 13 Jul 2009 Results were presented during a late-breaking clinical trial session at the 22nd Congress of the International Society on Thrombosis and Haemostasis.
    • 13 Jul 2009 Primary composite endpoint (deep vein thrombosis, pulmonary embolism, death rate) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top